Advertisement
U.S. markets open in 1 hour 33 minutes
  • S&P Futures

    5,303.25
    -5.00 (-0.09%)
     
  • Dow Futures

    40,128.00
    -16.00 (-0.04%)
     
  • Nasdaq Futures

    18,481.00
    -22.75 (-0.12%)
     
  • Russell 2000 Futures

    2,139.10
    +0.70 (+0.03%)
     
  • Crude Oil

    82.44
    +1.09 (+1.34%)
     
  • Gold

    2,230.00
    +17.30 (+0.78%)
     
  • Silver

    24.66
    -0.09 (-0.37%)
     
  • EUR/USD

    1.0786
    -0.0043 (-0.40%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    13.03
    +0.25 (+1.96%)
     
  • GBP/USD

    1.2614
    -0.0024 (-0.19%)
     
  • USD/JPY

    151.3530
    +0.1070 (+0.07%)
     
  • Bitcoin USD

    70,696.91
    +463.70 (+0.66%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.37
    +20.39 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Glaukos (GKOS) Up on Positive Glaucoma Study Data on iDose TR

Glaukos Corporation GKOS announced positive top-line data from two pivotal studies evaluating its targeted injectable implant candidate — iDose TR — in glaucoma patients. Data from the studies showed that the slow-release iDose TR achieved excellent tolerability and a favorable safety profile. The candidate achieved non-inferior reductions in intraocular pressure (IOP) in three months from baseline compared to the timolol ophthalmic solution.

Price Performance

Shares of Glaukos rallied 18.5% on Sep 7, following the data readout. Shares of the company have gained 28.2% so far this year against the industry’s 32.4% fall and the S&P 500's 18.7% decline.

Based on these data, the company is planning to file a new drug application (NDA), seeking approval for iDose TR from the FDA by the end of 2023.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Study Data

Two phase III studies — GC-010 and GC-012 — evaluated both fast- and slow-release iDose TR in two separate arms for a reduction in IOP in patients with open-angle glaucoma (OAG) or ocular hypertension. Data from the studies showed that both fast- and slow-release iDose TR achieved the pre-specified primary efficacy endpoint of non-inferiority to the active comparator arm.

The slow-release iDose TR achieved 6.6-8.5 mmHg and 6.7-8.4 mmHg reductions in IOP from baseline in GC-010 and GC-012 studies compared with timolol’s reduction of 6.6-7.7 mmHg and 6.8-7.2 mmHg, respectively, in three months.

Moreover, 93% of the patients treated with slow-release iDose TR remained well-controlled on the same or fewer IOP-lowering topical medications at 12 months compared to 67% of the patients receiving timolol. Among patients treated with slow-release iDose TR, 81% were completely free of IOP-lowering topical medications at 12 months.

Based on the data from the two studies, Glaukos believes that iDose TR can be a transformative novel technology that will be able to fundamentally improve the glaucoma treatment paradigm for patients. Per the company, there is an important unmet clinical need within this ophthalmic community for safe, effective and sustained dropless pharmaceutical alternatives to traditional topical medications. This will likely result in strong demand for treatments like iDose TR.

Glaukos Corporation Price

Glaukos Corporation Price
Glaukos Corporation Price

Glaukos Corporation price | Glaukos Corporation Quote

Glaukos plans to file the NDA for the slow-release iDose TR model.

iDose TR is a novel formulation of travoprost, a prostaglandin analog used to reduce IOP. iDose TR is designed in a way that it can be replaced with a new unit following the release of the travoprost contained in the device. The company is developing the device as an alternative to daily eye drop treatment.

Zacks Rank & Key Picks

Currently, Glaukos carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. AMN, ShockWave Medical, Inc. SWAV and McKesson Corporation MCK.

AMN Healthcare, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 3.2%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 15.7%.

You can see the complete list of today’s Zacks #1 Rank stocks here.

AMN Healthcare has lost 10.1% compared with the industry’s 37.4% fall in the past year.

ShockWave Medical, sporting a Zacks Rank #1 at present, has an estimated growth rate of 33.1% for 2023. SWAV’s earnings surpassed estimates in all the trailing four quarters, the average beat being 180.1%.

ShockWave Medical has gained 20.1% against the industry’s 34.1% fall over the past year.

McKesson, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 9.9%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average beat being 13%.

McKesson has gained 75% against the industry’s 16.3% fall over the past year.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
McKesson Corporation (MCK) : Free Stock Analysis Report
 
AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report
 
Glaukos Corporation (GKOS) : Free Stock Analysis Report
 
ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement